Search bioRxiv⌕ Search

Biology subjects

Korzinkin, M.

Publications and source records attributed to Korzinkin, M..

3 recordsLinked to original sources

DORA AI Scientist: Multi-agent Virtual Research Team for Scientific Exploration Discovery and Automated Report Generation

Modern goal-oriented scientific research process involves hierarchical teams of researchers of diverse backgrounds performing generalist and domain-specific tasks. Many of these tasks include hypothesis generation, literature review, data collection, cleanup, processing and analysis, experimental design, virtual and physical experiments, research report and academic paper writing, reference management, bibliography and quality control. Most of these tasks can be performed automatically or in a co-pilot mode by the generative reinforcement learning systems. In this paper, we introduce a versatile multi-agent scientific exploration and draft outline research assistant (DORA), which provides multiple templates and workflows for automated or semi-automated research studies and report generation. Under user guidance, it employs hierarchical teams of AI agents based on the plug-and-play generalist and domain-specific large language models (LLMs) exploiting a variety of specialized research tools and open data repositories and generates high-quality research outputs publication drafts with maximally-accurate references. DORA is designed to minimize the time and effort required for manuscript preparation, thereby enabling researchers to devote more attention to high-value discovery tasks. The system is constantly evolving with user feedback with regular feature and resource updates. The platform is available at https://dora.insilico.com.

bioinformatics↗

Designing a multi-serotype Dengue virus vaccine: an in silico approach to broad-spectrum immunity

Dengue virus infection represents a major global health issue, with four distinct serotypes complicating the challenge of developing a vaccine due to the need for balanced, long-lasting immunity against all serotypes. Current vaccines have limitations, including an increased risk of severe dengue in seronegative individuals and moderate efficacy, highlighting the need for more effective solutions. Our study aimed to design a multi-serotype Dengue virus vaccine using a computational approach to achieve broad-spectrum immunity. We employed advanced computational tools and algorithms to predict B-cell and T-cell epitopes, ensuring the selection of antigenic targets that provide comprehensive protection against all four serotypes. The methodology included tools for B-cell epitope prediction, tools for MHC class II and I peptide predictions, and tools for toxicity and allergenicity screening to ensure the safety of the vaccine candidates. Our results identified 21 B-cell epitopes, 15 CTL peptides, and 12 HTL peptides, validated for safety regarding toxicity and allergenic potential. The vaccine construct incorporated the adjuvant {beta}-defensin-3 and specific linkers to enhance immunogenicity and stability. Tertiary structure prediction, Ramachandran plot analysis, and stereochemical examination confirmed the stability and quality of the vaccine model. These findings demonstrate the potential of computational methods in addressing the complex challenges of Dengue virus vaccine development. Our computational approach offers a novel pathway for vaccine design, potentially accelerating the development of effective multi-serotype vaccines. This study provides a promising foundation for future research and clinical validation, marking a significant step forward in dengue vaccine development.

immunology↗

Comparative analysis of Endoxifen, Tamoxifen and Fulvestrant: A Bioinformatics Approach to Uncover Mechanisms of Action in Breast Cancer

Breast cancer remains a significant health challenge, with estrogen receptor positive (ER+) subtypes being particularly prevalent forms of breast cancer. Current anti-estrogen therapies, such as tamoxifen and fulvestrant, have limitations, including partial agonist activity and resistance development, which evidence the need for more potent alternatives. Endoxifen, a metabolite of tamoxifen, has emerged as a promising breast cancer therapeutic candidate due to its superior anti-estrogenic effects and side effect profile. The omics signatures for endoxifen, tamoxifen and fulvestrant, obtained from publicly available datasets, were aggregated and harmonized by means of the PandaOmics platform, a commercially available target-discovery platform using multiple AI engines including generative pretrained transformers. Pathway enrichment analyses provided insight into these agents mechanisms of action (MOA) in breast cancer. The analyses revealed unexpected variances in several key pathways from expected interactions via estrogen-dependent and independent effects. All three drugs downregulated estrogen signaling and cell cycle-related pathways, such as E2F targets, G2-M checkpoints, Myc targets, and mitotic spindle, and stimulated apoptosis. Fulvestrant and tamoxifen activated pro-inflammatory and immune pathways and perturbed epithelial-mesenchymal transition (EMT). Endoxifen perturbed the PI3K/Akt/mTORC1 pathway, pursuant to distinct molecular mechanisms compared to its parent compound, tamoxifen, and fulvestrant. In summary, advanced AI-driven methodologies demonstrate the capacity to analyze multi-omics data in a comparative way to advance the understanding of endocrine therapy mechanisms in breast cancer. This insight into the distinct effects of endoxifen, tamoxifen, and fulvestrant may aid in selecting the most effective therapies for specific indications and in identifying drug-specific biomarkers.

cancer biology↗